Nestlé Health Science has acquired a stake in US firm Accera to support ongoing trials and rollout of the firm's key brand, Axona.
Axona is a medical food intended for the clinical dietary management of mild to moderate Alzheimer’s disease, already on the market in the US.
“Our stake in Accera is a strategic step forward in building up our brain health portfolio,” said Nestlé Health Science president and CEO, Luis Cantarell. “Axona is an innovative medical food with a well understood mode of action and offers the potential for personalised nutrition for AD patients."
Nestlé Health Science has made several acquisitions and investments, including Vitaflo, CM&D Pharma Ltd and Prometheus Laboratories.
It holds a minority stake in Vital Foods, a New Zealand company that specialises in the development of kiwifruit-based solutions for gastrointestinal conditions.
- Douwe Egberts redesigns packaging to reflect UTZ certification
- GlaxoSmithKline repositions Revive from Lucozade to drive sales
- Rabobank identifies three forces driving the hybrid consumer trend